Comment: Access to essential medicines - promoting human rights over free trade and intellectual property claims

International Public Goods and Transfer of Technology Under a Globalized Intellectual Property Regime

Volumn , Issue , 2005, Pages 481-492

  Klug, Heinz ^a  

^a UNIVERSITY OF WISCONSIN LAW SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927028951     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511494529.024     Document Type: Chapter

References (37)

1. C. CORREA, INTELLECTUAL PROPERTY RIGHTS, THE WTO AND DEVELOPING COUNTR I E S: THE TRIPS AGREEMENT AND POLICY OPTIONS (Zed Books 2000).
2. A. De Waal, Why the HIV/AIDS Pandemic is a Structural Threat to Africa’s Governance and Economic Development, 27 FLETCHER F. OF WORLD AFF. 6 (2003).
3. Global AIDS Treatment Emergency Requires Urgent Response –No More Business as Usual (2003), available at http://www.who.int/mediacentre/releases/2003/pr67/en/print.html (visited 26 Sept. 2003).
4. I. Kaul & R.U. Mendoza, Advancing the Concept of Public Goods, in PROVIDING GLOBAL PUBL I C GOODS: MANAGING GLOBALIZATION 78-84 (Inge Kaul et al. eds., Oxford 2003).
5. Robert Sherwood, A Larger Context for Considering Pharmaceutical Patents in Developing
6. Countries, 15WORLD BULL. 76 (Jan.-Dec. 1999) (Institute of International Legal Studies, University of Philippines Law Center).
7. H.E. Bale, Patent Protection and Pharmaceutical Innovation, 29 N.Y.U. J. INT’ L L. & POL. 95 (1997);
8. International Federation of Pharmaceutical Manufacturers Associations (IFPMA), TRIPS, Pharmaceuticals and Developing Countries: Implications for Health Care Access, Drug Quality and Drug Development (2000), available at http://www.ifpma.org/admin/
9. MediaServer.jser?@_ID=431&@_MODE=GLB%20(2000).
10. Henry Grabowski, Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act [this volume].
11. Laurence R. Helfer, Regime Shifting: The TRIPS Agreement and New Dynamics of International Intellectual Property Lawmaking, 29 YALE J. IN’ L L. 1 (2004).
12. JAYASHREE WATAL, INTELLECTUAL PROPERTY RIGHTS IN THE WTO AND DEVELOPING COUNTR I E S (Kluwer Law International 2001).
13. Peter Drahos & John Braithwaite, INFORMAT ION FEUDALISM: WHO OWNS THE KNOWLEDGE ECONOMY? (New Press 2002).
14. SUSAN S ELL, PRIVATE POWER, PUBLIC LAW: THE GLOBALIZATION OF INTELLECTUAL PROPERTY RIGHTS (Cambridge University Press 2003).
15. JOOST PAUWELYN, CONFLICT OF NORMS IN PUBLIC INTERNAT IONAL LAW: HOW WTO LAW RELATES TO OTHER RULES OF INTERNATIONAL LAW 158–236 (2003).
16. World Health Organization (WHO), Concepts of Health Development, WHO 50 TH (1998), at www.who.int/archives/who50/en/concepts.htm.
17. Dr. M. Scholtz, International Trade Agreements and Public Health: WHO’s Role, Paper Presented at the Conference on Increasing Access to Essential Drugs in a Globalized Economy, at 1 (Amsterdam, 25–26 Nov. 1999), available at http://www.who.int/medicines/docs/WTO_Public_Health_Amsterdam_MS.html.
18. World Health Organization, WHO 50th: Concepts of Health Development (1998), at www.who.int/archives/who50/en/concepts.htm (last visited 3 Oct. 2003).
19. World Health Organization, The Use of Essential Drugs, Ninth Report of the WHO Expert Committee (including the Tenth Model List of Essential Drugs), Technical Report Series, No. 895 (2000).
20. P. Danzon & A. Towse, Theory and Implementation of Differential Pricing for Pharmaceuticals [this volume].
21. Edwin Cameron, First Jonathan Mann Memorial Lecture: The Deafening Silence of AIDS, XIIIth International AIDS Conference, Durban, South Africa, 9–14 July 2000, available at http://www.tac.org.za/newsletter/2000/ns000717.txt
22. WHO, Department of Essential Medicines, Updating and Disseminating theWHOModel List of Essential Drugs: The Way Forward, draft (22 June 2001), available at http://www.who.int/medicines/organization/par/edl/orgedldev.html.
23. M. RYAN, KNOWLEDGE DI PLOMACY: GLOBAL COMPETITION AND THE POLITICS OF INTELLECTUAL PROPERTY 5 (Brookings Institution 1998).
24. Dr. G.H. Brundtland (Director-General of the WHO), International Trade Agreements and Public Health: WHO’s Role, presented by video at the Conference on Increasing Access to Essential Drugs in a Globalized Economy (Amsterdam, 25–26 Nov. 1999), at 1, available at http://www.who.int/medicines/docs/WTO_Public_Health_Amsterdam_GHB.html.
25. Jonathan Mann et al., Health and Human Rights, in HEALTH AND HUMAN RI GHTS 7 (J. Mann et al. eds., Routledge 1999).
26. Rebecca Cook, Gender, Health and Human Rights, in HEALTH AND HUMAN RIGHTS 262 (J. Mann et al. eds., Routledge 1999).
27. D. FIDLER, INTERNAT IONAL LAW AND PUBL I C HEALTH: MATERIALS ON AND ANALYS I S OF GLOBAL HEALTH JURI SPRUDENCE 118 (Transnational Publishers 2000).
28. WHO & UNICEF, Declaration of Alma-Ata, Report of the International Conference on Primary Health Care (1978).
29. J. BRAITHWA ITE & P. DRAHOS, GLOBAL BUSINE S S REGULATION 360–398 (Cambridge University Press 2000).
30. G. WALT, HEALTH POLICY: AN INTRODUCTION TO PROCESS AND POWER (University of the Witwatersrand Press 1994);
31. G. Walt, Globalization of International Health, 351 LANCET 434 (7 Feb. 1998).
32. M. Adelman & S. Baldia, Prospects and Limits of the Patent Provision in the TRIPS Agreement: The Case of India, 29 VAND. J. TRANSNAT’ L L. 507 (1996).
33. Paul Blustein, Drug Patents Dispute Poses Trade Threat; Generics Fight Could Derail WTO Accord, WASH. POST, 26 Oct. 2001.
34. Kavaljit Singh, Anthrax, Drug Transnationals and TRIPS: Profits Before Public Health, Z Magazine (December 2001), 39–42.
35. Carlos M. Correa, Implementation of the WTO General Council Decision on Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health (Draft, December 2003).
36. Carlos M. Correa, Implications of the Doha Declaration on the TRIPS Agreement and Public Health, Health Economics and Drugs, EDM Series No. 12, WHO/EDM/PAR/2002.3 (WHO June 2002).
37. Press Release, 28 Apr. 2004, Canada Proceeds with Bill C-9 on Cheaper Medicines Exports: NGOs Say Initiative is Important, and Urge Other Countries to Avoid the Flaws in the Canadian Model, available at www.aidslaw.ca/Media/press-release/e-press-apr2804.pdf.